Healthcare & Life Sciences
Oxford BioTherapeutics
United Kingdomwww.oxfordbiotherapeutics.com
activeseries-b
series-b
Stage
2015
Founded
3
Investors
About
Oxford BioTherapeutics is a clinical-stage oncology company developing first-in-class antibody-based therapies, including Antibody-Drug Conjugates (ADCs) and T-cell engagers (TCEs), to improve patient outcomes in cancer treatment.
Explore Oxford BioTherapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.